4 week treatment [G/P+/-Rbv] for hepatitis C - a randomized controlled trial (4RIBC)

Conference Reports for NATAP

The International Liver Congress™
EASL - European Association for the
Study of the Liver
2019 April 10-14
Vienna Austria


4 week treatment [G/P+/-Rbv] for hepatitis C - a randomized controlled trial (4RIBC)

	Reported by Jules Levin EASL 219 April 10-14 Vienna